AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
This study drug (Amrubicin) is believed to work by stopping the tumor cells in your body from
growing. The purpose of this study is to evaluate the effect of amrubicin compared to
topotecan in the treatment of small cell lung cancer.